[
  {
    "patient_id": "1",
    "patient_data": {
      "ID": 1,
      "beschreibung": "G1-Case",
      "tumorboard_datum ": 12.2024,
      "main_diagnosis_text": "NET des Dünndarms mit Lymphknoten und Lebermetastasen (ED 2015)\nKoloskopie bei unklaren abdominellen Beschwerden 06/2015: Tumor im Ileum 25 cm oberhalb der Ileozökalklappe. G1 NET.\n07/2015 CT staging Thorax/Abdomen: Primärtumor des Ileums 40 x 40 x 70 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.\n\n07/2015 Resektion der Lebermetastasen in Segment VI und Ablation der Läsion in Segment VIII. Hemicolektomie rechts und Ileumteilresektion mit Lymphadenektomie.\n01/2017 V.a. neue Lebermetastase\n02/2017 Start Somatoline\n02/2018 CT Abdomen: stable disease\n03/2019 CT Abdomen: V.a. gering progrediente Lebermetastasen. ",
      "Fragestellung": "Weitere Therapie?",
      "Empfehlung": "PET- Bildgebung und PRRT planen."
    },
    "matches_found": 11,
    "matches_with_publications": 11,
    "matches_with_posted_results": 11,
    "llm_evaluation_method": "google/gemma-3-27b-it:free",
    "min_relevance_score": 1.0,
    "matches": [
      {
        "nct_id": "NCT03375320",
        "title": "Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE3",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with neuroendocrine tumors, and the patient has a well-differentiated NET of the small intestine with liver metastases, fitting the tumor type criteria. While the patient's age, ECOG status, and biomarker data are unavailable, the inclusion/exclusion criteria do not immediately rule them out based on the provided information (e.g., no mention of prior cabozantinib use, no contraindications like severe heart failure are apparent). Cabozantinib could be a useful treatment option given the patient's progression on somatostatin analogs and the need for further therapy. The study has published results in a peer-reviewed journal, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Carcinoid Tumor; Functioning Pancreatic Neuroendocrine Tumor; Intermediate Grade Lung Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Tumor G1; Locally Advanced Lung Neuroendocrine Neoplasm; Locally Advanced Pancreatic Neuroendocrine Tumor; Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm; Low Grade Lung Neuroendocrine Neoplasm; Lung Neuroendocrine Tumor; Lung Neuroendocrine Tumor G2; Metastatic Digestive System Neuroendocrine Neoplasm; Metastatic Digestive System Neuroendocrine Tumor G1; Metastatic Lung Neuroendocrine Neoplasm; Metastatic Lung Neuroendocrine Tumor; Metastatic Pancreatic Neuroendocrine Neoplasm; Metastatic Pancreatic Neuroendocrine Tumor; Metastatic Thymus Neuroendocrine Neoplasm; Neuroendocrine Neoplasm; Neuroendocrine Tumor G2; Non-Functioning Pancreatic Neuroendocrine Tumor; Pancreatic Serotonin-Producing Neuroendocrine Tumor; Thymus Neuroendocrine Tumor; Unresectable Digestive System Neuroendocrine Neoplasm; Unresectable Digestive System Neuroendocrine Tumor G1; Unresectable Lung Neuroendocrine Neoplasm; Unresectable Pancreatic Neuroendocrine Neoplasm; Unresectable Thymus Neuroendocrine Neoplasm",
        "intervention": "Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging; Placebo Administration; Quality-of-Life Assessment; X-Ray Imaging",
        "url": "https://clinicaltrials.gov/study/NCT03375320",
        "publications": {
          "nct_id": "NCT03375320",
          "study_title": "Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "33152282",
              "citation": "Kunz PL. Angiogenesis inhibitors in neuroendocrine tumours: finally coming of age. Lancet Oncol. 2020 Nov;21(11):1395-1397. doi: 10.1016/S1470-2045(20)30560-X. No abstract available.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33152282/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT01578239",
        "title": "A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours",
        "status": "COMPLETED",
        "phase": "PHASE3",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study focuses on midgut carcinoid tumors, which aligns with the patient’s diagnosis of a small intestinal NET. The patient’s history of progressing disease despite somatostatin analog treatment (Somatoline) fits the inclusion criteria requiring progression on Octreotide LAR. While specific biomarker data (Ki67) and ECOG/age are missing, the patient’s history doesn’t immediately suggest exclusion based on the provided criteria. The intervention (Lutathera) represents a potentially useful alternative treatment option given disease progression. Finally, the study is a Phase 3 trial with published results, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Carcinoid Tumor of the Small Bowel; Neuroendocrine Tumour",
        "intervention": "Octreotide LAR; 177Lu-DOTA0-Tyr3-Octreotate",
        "url": "https://clinicaltrials.gov/study/NCT01578239",
        "publications": {
          "nct_id": "NCT01578239",
          "study_title": "A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours",
          "publications_found": 4,
          "publications": [
            {
              "pmid": "34793718",
              "citation": "Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34793718/"
            },
            {
              "pmid": "32123969",
              "citation": "Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, Baum RP, Caplin M, Ruszniewski P, Delpassand E, Hobday T, Verslype C, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Paganelli G, Severi S, Morse M, Metz DC, Ansquer C, Courbon F, Al-Nahhas A, Baudin E, Giammarile F, Taieb D, Mittra E, Wolin E, O'Dorisio TM, Lebtahi R, Deroose CM, Grana CM, Bodei L, Oberg K, Polack BD, He B, Mariani MF, Gericke G, Santoro P, Erion JL, Ravasi L, Krenning E; NETTER-1 study group. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2372-2382. doi: 10.1007/s00259-020-04709-x. Epub 2020 Mar 2.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32123969/"
            },
            {
              "pmid": "29878866",
              "citation": "Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E; NETTER-1 Study Group. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol. 2018 Sep 1;36(25):2578-2584. doi: 10.1200/JCO.2018.78.5865. Epub 2018 Jun 7.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/29878866/"
            },
            {
              "pmid": "28076709",
              "citation": "Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Oberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28076709/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT01970540",
        "title": "Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors",
        "status": "COMPLETED",
        "phase": "PHASE1",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The inclusion criteria explicitly list 'Gastroenteropancreatic neuroendocrine tumors', which directly matches the patient's diagnosis of a small intestinal NET. While the patient's ECOG and age are not specified, the study allows for ECOG ≤ 1 (or ≤2 for certain cohorts) and an age range of 18-75, suggesting the patient may be eligible. The combination of lurbinectedin and doxorubicin could be a potential treatment option given the progression of the patient’s disease despite somatostatin analogs, and the study has published results, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Endometrial Adenocarcinomas; Neuroendocrine Tumors; Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy",
        "intervention": "lurbinectedin (PM01183); Doxorubicin",
        "url": "https://clinicaltrials.gov/study/NCT01970540",
        "publications": {
          "nct_id": "NCT01970540",
          "study_title": "Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "33704620",
              "citation": "Olmedo ME, Forster M, Moreno V, Lopez-Criado MP, Brana I, Flynn M, Doger B, de Miguel M, Lopez-Vilarino JA, Nunez R, Kahatt C, Cullell-Young M, Zeaiter A, Calvo E. Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study. Invest New Drugs. 2021 Oct;39(5):1275-1283. doi: 10.1007/s10637-020-01025-x. Epub 2021 Mar 11.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33704620/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02875223",
        "title": "A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas",
        "status": "TERMINATED",
        "phase": "PHASE1",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes grade 2 NETs, and the patient has a G1 NET of the small intestine, which could potentially be considered within the scope of NETs investigated. The inclusion criteria of advanced/unresectable tumors aligns with the patient’s current situation of potentially progressing liver metastases. Assuming the patient has an ECOG of 0-1 and doesn't meet any of the exclusion criteria (no recent transplant, no uncontrolled ulcers, good cardiac/bone marrow function), they would be eligible. CC-90011 represents a potentially useful new intervention given prior somatostatin analogue treatment and disease progression, and the study has published results in peer-reviewed journals, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Lymphoma, Non-Hodgkin; Neoplasms",
        "intervention": "CC-90011; Rifampicin; Itraconazole",
        "url": "https://clinicaltrials.gov/study/NCT02875223",
        "publications": {
          "nct_id": "NCT02875223",
          "study_title": "A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas",
          "publications_found": 2,
          "publications": [
            {
              "pmid": "33046517",
              "citation": "Hollebecque A, Salvagni S, Plummer R, Isambert N, Niccoli P, Capdevila J, Curigliano G, Moreno V, Martin-Romano P, Baudin E, Arias M, Mora S, de Alvaro J, Di Martino J, Parra-Palau JL, Sanchez-Perez T, Aronchik I, Filvaroff EH, Lamba M, Nikolova Z, de Bono JS. Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. Clin Cancer Res. 2021 Jan 15;27(2):438-446. doi: 10.1158/1078-0432.CCR-20-2380. Epub 2020 Oct 12.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33046517/"
            },
            {
              "pmid": "35737639",
              "citation": "Hollebecque A, Salvagni S, Plummer R, Niccoli P, Capdevila J, Curigliano G, Moreno V, de Braud F, de Villambrosia SG, Martin-Romano P, Baudin E, Arias M, de Alvaro J, Parra-Palau JL, Sanchez-Perez T, Aronchik I, Filvaroff EH, Lamba M, Nikolova Z, de Bono JS. Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies. Cancer. 2022 Sep 1;128(17):3185-3195. doi: 10.1002/cncr.34366. Epub 2022 Jun 23.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35737639/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT01782443",
        "title": "Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes neuroendocrine tumors, and the patient has a well-differentiated NET of the small intestine. The inclusion criteria regarding prior treatments (allowing prior somatostatin analogs and other therapies) and disease progression within 12 months seem to align with the patient’s history of stable disease followed by possible progression. The intervention, Ziv-aflibercept, is a potentially useful targeted therapy given the patient’s progressing disease despite somatostatin analog treatment. Finally, the study is completed and has published results, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Carcinoid Tumor",
        "intervention": "Ziv-aflibercept",
        "url": "https://clinicaltrials.gov/study/NCT01782443",
        "publications": {
          "nct_id": "NCT01782443",
          "study_title": "Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "36395401",
              "citation": "Perez K, Kulke MH, Horick NK, Regan E, Graham C, Scheutz S, Stonely D, Enzinger PC, Fuchs CS, Allen JN, Enzinger AC, Clark JW, Chan JA. A Phase II Study of Ziv-Aflibercept in Patients With Advanced Extrapancreatic Neuroendocrine Tumors. Pancreas. 2022 Aug 1;51(7):763-768. doi: 10.1097/MPA.0000000000002099.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/36395401/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03034200",
        "title": "Phase 2 Study of ONC201 in Neuroendocrine Tumors",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes neuroendocrine tumors, and the patient has a well-documented history of a small intestinal NET with liver metastases. The inclusion criteria do not immediately rule the patient out – there’s no age limit specified that would exclude them, and the study allows for prior therapies. While the patient’s ECOG is unknown, the Karnofsky score requirement of ≥60% suggests a reasonable performance status is needed, which is plausible. ONC201 represents a potentially useful intervention given the patient’s progressive disease despite somatostatin analogue treatment, and the study has published results in peer-reviewed journals, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Recurrent Neuroendocrine Tumor; Metastatic Neuroendocrine Tumor",
        "intervention": "ONC201",
        "url": "https://clinicaltrials.gov/study/NCT03034200",
        "publications": {
          "nct_id": "NCT03034200",
          "study_title": "Phase 2 Study of ONC201 in Neuroendocrine Tumors",
          "publications_found": 8,
          "publications": [
            {
              "pmid": "23390247",
              "citation": "Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, Zhou JY, Wu GS, El-Deiry WS. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013 Feb 6;5(171):171ra17. doi: 10.1126/scitranslmed.3004828.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/23390247/"
            },
            {
              "pmid": "25927855",
              "citation": "Allen JE, Krigsfeld G, Patel L, Mayes PA, Dicker DT, Wu GS, El-Deiry WS. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Mol Cancer. 2015 May 1;14:99. doi: 10.1186/s12943-015-0346-9.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25927855/"
            },
            {
              "pmid": "25681273",
              "citation": "Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. Cancer Res. 2015 Apr 15;75(8):1668-74. doi: 10.1158/0008-5472.CAN-14-2356. Epub 2015 Feb 13.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25681273/"
            },
            {
              "pmid": "27602582",
              "citation": "Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 2016 Nov 8;7(45):74380-74392. doi: 10.18632/oncotarget.11814.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27602582/"
            },
            {
              "pmid": "29626752",
              "citation": "Hayes-Jordan AA, Ma X, Menegaz BA, Lamhamedi-Cherradi SE, Kingsley CV, Benson JA, Camacho PE, Ludwig JA, Lockworth CR, Garcia GE, Craig SL. Efficacy of ONC201 in Desmoplastic Small Round Cell Tumor. Neoplasia. 2018 May;20(5):524-532. doi: 10.1016/j.neo.2018.02.006. Epub 2018 Apr 5.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/29626752/"
            },
            {
              "pmid": "28767654",
              "citation": "Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLB, Van den Heuvel APJ, Lev A, Garnett MJ, McDermott U, Benes CH, Batchelor TT, Chi AS, Elemento O, Allen JE, El-Deiry WS. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. PLoS One. 2017 Aug 2;12(8):e0180541. doi: 10.1371/journal.pone.0180541. eCollection 2017.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28767654/"
            },
            {
              "pmid": "30907145",
              "citation": "Anderson PM, Hanna R. Defining Moments: Making Time for Virtual Visits and Catalyzing Better Cancer Care. Health Commun. 2020 May;35(6):787-791. doi: 10.1080/10410236.2019.1587695. Epub 2019 Mar 24.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30907145/"
            },
            {
              "pmid": "35022321",
              "citation": "Anderson PM, Trucco MM, Tarapore RS, Zahler S, Thomas S, Gortz J, Mian O, Stoignew M, Prabhu V, Morrow S, Allen JE. Phase II Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma and Desmoplastic Small Round Cell Tumor. Clin Cancer Res. 2022 May 2;28(9):1773-1782. doi: 10.1158/1078-0432.CCR-21-4030.",
              "type": "RESULT",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35022321/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02075606",
        "title": "Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients",
        "status": "COMPLETED",
        "phase": "PHASE4",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The patient has a functioning midgut NET, matching the study's inclusion criteria. While the patient's ECOG and age are unknown, the study doesn't explicitly exclude patients based on these factors, and the patient is over 18. The patient is currently on Somatuline (lanreotide acetate), aligning with the study's intervention. The exclusion criteria regarding prior therapies (washout periods) and other treatments need further clarification based on the patient’s full treatment history, but don't immediately rule them out. The study has published results in peer-reviewed journals, indicating good scientific quality and potentially useful information regarding treatment response and progression-free survival.",
        "has_posted_results": true,
        "condition": "NeuroEndocrine Tumours",
        "intervention": "lanreotide acetate",
        "url": "https://clinicaltrials.gov/study/NCT02075606",
        "publications": {
          "nct_id": "NCT02075606",
          "study_title": "Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients",
          "publications_found": 2,
          "publications": [
            {
              "pmid": "35132704",
              "citation": "Meyer T, Caplin M, Khan MS, Toumpanakis C, Shetty S, Ramage JK, Houchard A, Higgs K, Shah T. Circulating tumour cells and tumour biomarkers in functional midgut neuroendocrine tumours. J Neuroendocrinol. 2022 Apr;34(4):e13096. doi: 10.1111/jne.13096. Epub 2022 Feb 7.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35132704/"
            },
            {
              "pmid": "27875519",
              "citation": "Childs A, Vesely C, Ensell L, Lowe H, Luong TV, Caplin ME, Toumpanakis C, Thirlwell C, Hartley JA, Meyer T. Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours. Br J Cancer. 2016 Dec 6;115(12):1540-1547. doi: 10.1038/bjc.2016.377. Epub 2016 Nov 22.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27875519/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02721732",
        "title": "Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The study explicitly includes 'other rare tumors' which could encompass a neuroendocrine tumor of the small intestine. The patient's history of progressing disease after initial resection and somatostatin analogue treatment aligns with the study's inclusion criterion of progression following standard therapies. The patient would need to meet the ECOG performance status and lab value criteria, but these are not explicitly exclusionary based on the provided information. Pembrolizumab, an anti-PD-1 agent, represents a potentially useful treatment option given the progression of the patient’s disease, and the study has published results in peer-reviewed journals, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Advanced Malignant Solid Neoplasm; Carcinoma of Unknown Primary; Metastatic Adrenal Gland Pheochromocytoma; Metastatic Kidney Medullary Carcinoma; Metastatic Malignant Germ Cell Tumor; Metastatic Malignant Solid Neoplasm; Metastatic Paraganglioma; Metastatic Penile Carcinoma; Metastatic Skin Squamous Cell Carcinoma; Small Cell Carcinoma; Stage III Adrenal Cortex Carcinoma AJCC v7; Stage IV Adrenal Cortex Carcinoma AJCC v7; Stage IV Penile Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Unresectable Adrenal Gland Pheochromocytoma; Unresectable Paraganglioma; Unresectable Skin Squamous Cell Carcinoma; Unresectable Solid Neoplasm; Vascular Neoplasm",
        "intervention": "Laboratory Biomarker Analysis; Pembrolizumab; Questionnaire Administration",
        "url": "https://clinicaltrials.gov/study/NCT02721732",
        "publications": {
          "nct_id": "NCT02721732",
          "study_title": "Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic",
          "publications_found": 12,
          "publications": [
            {
              "pmid": "35999229",
              "citation": "Mendoza TR, Hong DS, Peterson CB, Stephen B, Dumbrava E, Pant S, Tsimberidou AM, Yap TA, Sheshadri A, Altan M, George G, Castillo L, Rodriguez E, Gong J, Subbiah V, Janku F, Fu S, Piha-Paul SA, Ahnert JR, Karp DD, Cleeland C, Meric-Bernstam F, Naing A. Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. Sci Rep. 2022 Aug 23;12(1):14367. doi: 10.1038/s41598-022-16588-3.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35999229/"
            },
            {
              "pmid": "35618285",
              "citation": "Raghav KP, Stephen B, Karp DD, Piha-Paul SA, Hong DS, Jain D, Chudy Onwugaje DO, Abonofal A, Willett AF, Overman M, Smaglo B, Huey RW, Meric-Bernstam F, Varadhachary GR, Naing A. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. J Immunother Cancer. 2022 May;10(5):e004822. doi: 10.1136/jitc-2022-004822.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35618285/"
            },
            {
              "pmid": "34725215",
              "citation": "Pant S, Moyers JT, Naing A. Letter to the editor from Pant et al. J Immunother Cancer. 2021 Nov;9(11):e003991. doi: 10.1136/jitc-2021-003991. No abstract available.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34725215/"
            },
            {
              "pmid": "34241781",
              "citation": "Ferrarotto R, Sousa LG, Qing Y, Kaya D, Stephen B, Jain D, Bell D, Pant S, Tsimberidou AM, Janku F, Blumenschein G, Glisson BS, Ahnert JR, Piha-Paul SA, Lee JJ, Wong MK, Lu C, Meric-Bernstam F, Naing A. Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial. Adv Ther. 2021 Aug;38(8):4581-4591. doi: 10.1007/s12325-021-01807-6. Epub 2021 Jul 9.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34241781/"
            },
            {
              "pmid": "33770291",
              "citation": "Hahn AW, Chahoud J, Campbell MT, Karp DD, Wang J, Stephen B, Tu SM, Pettaway CA, Naing A. Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial. Invest New Drugs. 2021 Oct;39(5):1405-1410. doi: 10.1007/s10637-021-01100-x. Epub 2021 Mar 26.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33770291/"
            },
            {
              "pmid": "33491277",
              "citation": "Tsimberidou AM, Vo HH, Subbiah V, Janku F, Piha-Paul S, Yilmaz B, Gong J, Naqvi MF, Tu SM, Campbell M, Meric-Bernstam F, Naing A. Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. Oncologist. 2021 Jul;26(7):558-e1098. doi: 10.1002/onco.13682. Epub 2021 Feb 12.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33491277/"
            },
            {
              "pmid": "33427689",
              "citation": "Majd N, Waguespack SG, Janku F, Fu S, Penas-Prado M, Xu M, Alshawa A, Kamiya-Matsuoka C, Raza SM, McCutcheon IE, Naing A. Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study. J Immunother Cancer. 2020 Dec;8(2):e001532. doi: 10.1136/jitc-2020-001532.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33427689/"
            },
            {
              "pmid": "33415580",
              "citation": "How JA, Jazaeri A, Westin SN, Sood AK, Ramondetta LM, Xu M, Abonofal A, Karp DD, Subbiah V, Stephen B, Rodon JA, Yang F, Naing A. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Invest New Drugs. 2021 Jun;39(3):829-835. doi: 10.1007/s10637-020-01043-9. Epub 2021 Jan 7.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33415580/"
            },
            {
              "pmid": "32534809",
              "citation": "Frumovitz M, Westin SN, Salvo G, Zarifa A, Xu M, Yap TA, Rodon AJ, Karp DD, Abonofal A, Jazaeri AA, Naing A. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecol Oncol. 2020 Sep;158(3):570-575. doi: 10.1016/j.ygyno.2020.05.682. Epub 2020 Jun 11.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32534809/"
            },
            {
              "pmid": "32303619",
              "citation": "Tapia C, Aung PP, Roy-Chowdhuri S, Xu M, Ouyang F, Alshawa A, Hajjar J, Singh G, Yang V, Castillo L, Le H, Murthy R, Stephen B, Hess KR, Wistuba I, Naing A. Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors. J Immunother Cancer. 2020 Apr;8(1):e000665. doi: 10.1136/jitc-2020-000665.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32303619/"
            },
            {
              "pmid": "32188704",
              "citation": "Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 Mar;8(1):e000347. doi: 10.1136/jitc-2019-000347.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32188704/"
            },
            {
              "pmid": "31533818",
              "citation": "Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, Fu S, Karp DD, Meric-Bernstam F, Naing A. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019 Sep 18;7(1):253. doi: 10.1186/s40425-019-0722-x.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/31533818/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03972488",
        "title": "Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE3",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The patient has a G1 NET of the small intestine with liver metastases, which falls under the GEP-NET category included in the study. While the study focuses on G2/G3 tumors, the patient's Ki67 index is unknown, and the study may still be considered if it falls within the acceptable range. The patient's history of somatostatin analog treatment (Somatoline) doesn't automatically exclude them, as the study included patients previously treated with SSAs without progression. Lutathera is a potentially useful treatment option given the patient's progressive disease and the study's positive results, as evidenced by the two publications and posted results indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Gastro-enteropancreatic Neuroendocrine Tumor",
        "intervention": "Lutathera; 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot); 2.5% Lys-Arg sterile amino acid solution; High dose 60 mg octreotide long-acting repeatable",
        "url": "https://clinicaltrials.gov/study/NCT03972488",
        "publications": {
          "nct_id": "NCT03972488",
          "study_title": "Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET",
          "publications_found": 2,
          "publications": [
            {
              "pmid": "38851203",
              "citation": "Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, Garcia-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5.",
              "type": "RESULT",
              "url": "https://pubmed.ncbi.nlm.nih.gov/38851203/"
            },
            {
              "pmid": "33973550",
              "citation": "Jungels C, Deleporte A. State of the art and future directions in the systemic treatment of neuroendocrine neoplasms. Curr Opin Oncol. 2021 Jul 1;33(4):378-385. doi: 10.1097/CCO.0000000000000740.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33973550/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT01524783",
        "title": "Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)",
        "status": "COMPLETED",
        "phase": "PHASE3",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The patient has a well-differentiated (G1) neuroendocrine tumor of the small intestine, which falls under the GI origin specified in the study’s inclusion criteria. While the patient’s prior therapies aren’t fully detailed, the study allows patients previously treated with SSA and one line of chemotherapy, which aligns with the patient’s somatostatin treatment. The ECOG performance status and age are unknown, but assuming they meet the study criteria (ECOG ≤1), the patient could be eligible. Everolimus is a potentially useful treatment option given disease progression, and the study has published results in peer-reviewed journals, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Advanced NET of GI Origin; Advanced NET of Lung Origin; Neuroendocrine Tumors",
        "intervention": "Everolimus; Placebo; Best suportive care (BSC)",
        "url": "https://clinicaltrials.gov/study/NCT01524783",
        "publications": {
          "nct_id": "NCT01524783",
          "study_title": "Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)",
          "publications_found": 5,
          "publications": [
            {
              "pmid": "33560090",
              "citation": "Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, Kulke MH, Pavel M, Singh S. Markers of Systemic Inflammation in Neuroendocrine Tumors: A Pooled Analysis of the RADIANT-3 and RADIANT-4 Studies. Pancreas. 2021 Feb 1;50(2):130-137. doi: 10.1097/MPA.0000000000001745.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33560090/"
            },
            {
              "pmid": "29081664",
              "citation": "Buzzoni R, Carnaghi C, Strosberg J, Fazio N, Singh S, Herbst F, Ridolfi A, Pavel ME, Wolin EM, Valle JW, Oh DY, Yao JC, Pommier R. Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. Onco Targets Ther. 2017 Oct 16;10:5013-5030. doi: 10.2147/OTT.S142087. eCollection 2017.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/29081664/"
            },
            {
              "pmid": "29055056",
              "citation": "Fazio N, Buzzoni R, Delle Fave G, Tesselaar ME, Wolin E, Van Cutsem E, Tomassetti P, Strosberg J, Voi M, Bubuteishvili-Pacaud L, Ridolfi A, Herbst F, Tomasek J, Singh S, Pavel M, Kulke MH, Valle JW, Yao JC. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Sci. 2018 Jan;109(1):174-181. doi: 10.1111/cas.13427. Epub 2017 Nov 9.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/29055056/"
            },
            {
              "pmid": "28838862",
              "citation": "Pavel ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, Degtyarev E, Neary MP, Carnaghi C, Tomasek J, Wolin E, Raderer M, Lahner H, Valle JW, Pommier R, Van Cutsem E, Tesselaar MET, Fave GD, Buzzoni R, Hunger M, Eriksson J, Cella D, Ricci JF, Fazio N, Kulke MH, Yao JC. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1411-1422. doi: 10.1016/S1470-2045(17)30471-0. Epub 2017 Aug 30.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28838862/"
            },
            {
              "pmid": "26703889",
              "citation": "Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016 Mar 5;387(10022):968-977. doi: 10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26703889/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02983045",
        "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
        "status": "COMPLETED",
        "phase": "PHASE1",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The inclusion criteria specify 'locally advanced or metastatic solid tumors,' which encompasses the patient's metastatic neuroendocrine tumor of the small intestine. While specific NET inclusion criteria are mentioned as potentially applying, the broad initial criteria are met. The patient's history of somatostatin analogs and surgery doesn't explicitly exclude them, assuming sufficient washout period from prior chemotherapy/biological therapy (which is unspecified in the patient data). The combination of NKTR-214 and nivolumab represents a potentially useful immunotherapy approach for progressive NET, and the study has published results in peer-reviewed journals, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Melanoma; Renal Cell Carcinoma; Non Small Cell Lung Cancer; Urothelial Carcinoma; Triple Negative Breast Cancer; HR+/HER2- Breast Cancer; Gastric Cancer",
        "intervention": "Dose Escalation Doublet: Combination of NKTR-214 + nivolumab; Dose Expansion Doublet: Combination of NKTR-214 + nivolumab; Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab; Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab",
        "url": "https://clinicaltrials.gov/study/NCT02983045",
        "publications": {
          "nct_id": "NCT02983045",
          "study_title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
          "publications_found": 3,
          "publications": [
            {
              "pmid": "35643589",
              "citation": "Siefker-Radtke AO, Cho DC, Diab A, Sznol M, Bilen MA, Balar AV, Grignani G, Puente E, Tang L, Chien D, Hoch U, Choudhury A, Yu D, Currie SL, Tagliaferri MA, Zalevsky J, Hurwitz ME, Tannir NM. Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02. Eur Urol. 2022 Oct;82(4):365-373. doi: 10.1016/j.eururo.2022.05.002. Epub 2022 May 25.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35643589/"
            },
            {
              "pmid": "34255535",
              "citation": "Diab A, Tykodi SS, Daniels GA, Maio M, Curti BD, Lewis KD, Jang S, Kalinka E, Puzanov I, Spira AI, Cho DC, Guan S, Puente E, Nguyen T, Hoch U, Currie SL, Lin W, Tagliaferri MA, Zalevsky J, Sznol M, Hurwitz ME. Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. J Clin Oncol. 2021 Sep 10;39(26):2914-2925. doi: 10.1200/JCO.21.00675. Epub 2021 Jul 13.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34255535/"
            },
            {
              "pmid": "33298619",
              "citation": "Veatch JR, Singhi N, Jesernig B, Paulson KG, Zalevsky J, Iaccucci E, Tykodi SS, Riddell SR. Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab. J Immunother Cancer. 2020 Dec;8(2):e001591. doi: 10.1136/jitc-2020-001591.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33298619/"
            }
          ],
          "status": "from_study_data"
        }
      }
    ],
    "report_file": "C:\\Users\\pia\\OneDrive - Universitaet Bern\\Projects\\NetTubo\\netTubo\\clinical_trials_matches\\patient_1_clinical_trials_llm.txt"
  },
  {
    "patient_id": "2",
    "patient_data": {
      "ID": 2,
      "beschreibung": "G3-Case Initialdiagnose, Netter 2 analo",
      "tumorboard_datum ": 8.2015,
      "main_diagnosis_text": "NET des Dünndarms mit Lymphknoten und Lebermetastasen (ED 2015)\nKoloskopie bei unklaren abdominellen Beschwerden 06/2015: Tumor im Ileum 25 cm oberhalb der Ileozökalklappe. G3 NET, Ki67 48%.\n07/2015 CT staging Thorax/Abdomen: Primärtumor des Ileums 40 x 40 x 70 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.\n\n07/2015 Hemicolektomie rechts und Ileumteilresektion mit Lymphadenektomie.",
      "Fragestellung": "Weitere Therapie?",
      "Empfehlung": "PET- Bildgebung und PRRT planen, analog zur Netter 2 Studie."
    },
    "matches_found": 7,
    "matches_with_publications": 7,
    "matches_with_posted_results": 7,
    "llm_evaluation_method": "google/gemma-3-27b-it:free",
    "min_relevance_score": 1.0,
    "matches": [
      {
        "nct_id": "NCT03375320",
        "title": "Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE3",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with neuroendocrine tumors, and the patient has a G3 NET of the small intestine with liver and lymph node metastases, fitting the inclusion criteria regarding tumor type and stage. While the patient's prior therapies and ECOG status are unknown, the inclusion criteria allow for patients who have progressed after one prior line of therapy, and do not explicitly exclude this patient based on the limited information available. Cabozantinib is a potentially useful treatment option for progressive NET, and the study has published results, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Carcinoid Tumor; Functioning Pancreatic Neuroendocrine Tumor; Intermediate Grade Lung Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Tumor G1; Locally Advanced Lung Neuroendocrine Neoplasm; Locally Advanced Pancreatic Neuroendocrine Tumor; Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm; Low Grade Lung Neuroendocrine Neoplasm; Lung Neuroendocrine Tumor; Lung Neuroendocrine Tumor G2; Metastatic Digestive System Neuroendocrine Neoplasm; Metastatic Digestive System Neuroendocrine Tumor G1; Metastatic Lung Neuroendocrine Neoplasm; Metastatic Lung Neuroendocrine Tumor; Metastatic Pancreatic Neuroendocrine Neoplasm; Metastatic Pancreatic Neuroendocrine Tumor; Metastatic Thymus Neuroendocrine Neoplasm; Neuroendocrine Neoplasm; Neuroendocrine Tumor G2; Non-Functioning Pancreatic Neuroendocrine Tumor; Pancreatic Serotonin-Producing Neuroendocrine Tumor; Thymus Neuroendocrine Tumor; Unresectable Digestive System Neuroendocrine Neoplasm; Unresectable Digestive System Neuroendocrine Tumor G1; Unresectable Lung Neuroendocrine Neoplasm; Unresectable Pancreatic Neuroendocrine Neoplasm; Unresectable Thymus Neuroendocrine Neoplasm",
        "intervention": "Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging; Placebo Administration; Quality-of-Life Assessment; X-Ray Imaging",
        "url": "https://clinicaltrials.gov/study/NCT03375320",
        "publications": {
          "nct_id": "NCT03375320",
          "study_title": "Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "33152282",
              "citation": "Kunz PL. Angiogenesis inhibitors in neuroendocrine tumours: finally coming of age. Lancet Oncol. 2020 Nov;21(11):1395-1397. doi: 10.1016/S1470-2045(20)30560-X. No abstract available.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33152282/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03736720",
        "title": "Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin",
        "status": "TERMINATED",
        "phase": "PHASE2",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with gastrointestinal neuroendocrine carcinoma, which aligns with the patient’s diagnosis of a small intestinal NET. The patient’s Ki67 of 48% falls within the study’s high-grade NET definition (20-100%). While the patient’s ECOG, age, and prior therapies are unknown, the inclusion criteria are not immediately exclusionary based on the available information. The intervention (liposomal irinotecan, fluorouracil, and leucovorin) represents a potentially useful treatment option given the patient’s progressed disease and the need for further therapy. Finally, the study has published results, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Locally Advanced Digestive System Neuroendocrine Carcinoma; Locally Advanced Pancreatic Neuroendocrine Carcinoma; Metastatic Digestive System Neuroendocrine Carcinoma; Metastatic Pancreatic Neuroendocrine Carcinoma; Refractory Digestive System Neuroendocrine Carcinoma; Refractory Pancreatic Neuroendocrine Carcinoma; Unresectable Digestive System Neuroendocrine Carcinoma; Unresectable Pancreatic Neuroendocrine Carcinoma",
        "intervention": "Fluorouracil; Leucovorin; Liposomal Irinotecan; Quality-of-Life Assessment",
        "url": "https://clinicaltrials.gov/study/NCT03736720",
        "publications": {
          "nct_id": "NCT03736720",
          "study_title": "Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "33835977",
              "citation": "Abstracts Presented at the 13th Annual Multidisciplinary Neuroendocrine Tumor Medical Virtual Symposium of the North American Neuroendocrine Tumor Society, October 2-3, 2020. Pancreas. 2021 Mar 1;50(3):441-467. doi: 10.1097/MPA.0000000000001763. No abstract available.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33835977/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT01970540",
        "title": "Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors",
        "status": "COMPLETED",
        "phase": "PHASE1",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The inclusion criteria explicitly list 'Gastroenteropancreatic neuroendocrine tumors', which directly matches the patient's diagnosis of a small intestinal NET with liver metastases. While the patient's ECOG and age are not specified, the study allows for ECOG 0-1 (or 0-2 for certain cohorts) and an age range of 18-75, so they may be eligible. The combination of lurbinectedin and doxorubicin could be a potential treatment option given the patient's question regarding further therapy, and the study has published results in a peer-reviewed journal, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Endometrial Adenocarcinomas; Neuroendocrine Tumors; Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy",
        "intervention": "lurbinectedin (PM01183); Doxorubicin",
        "url": "https://clinicaltrials.gov/study/NCT01970540",
        "publications": {
          "nct_id": "NCT01970540",
          "study_title": "Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "33704620",
              "citation": "Olmedo ME, Forster M, Moreno V, Lopez-Criado MP, Brana I, Flynn M, Doger B, de Miguel M, Lopez-Vilarino JA, Nunez R, Kahatt C, Cullell-Young M, Zeaiter A, Calvo E. Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study. Invest New Drugs. 2021 Oct;39(5):1275-1283. doi: 10.1007/s10637-020-01025-x. Epub 2021 Mar 11.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33704620/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02875223",
        "title": "A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas",
        "status": "TERMINATED",
        "phase": "PHASE1",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes NET patients, specifically enriched for grade 2 NETs, and the patient has a G3 NET of the small intestine. While the patient's Ki67 is high (48%), suggesting a more aggressive tumor than grade 2, the study still includes patients with advanced/unresectable tumors. The inclusion criteria of ECOG 0-1 and absence of specific comorbidities don't immediately rule the patient out, although the patient's ECOG and age are currently unknown. CC-90011 represents a potentially useful novel therapy for relapsed/refractory disease, addressing the clinical question of further treatment options. Finally, the study has published results in peer-reviewed journals, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Lymphoma, Non-Hodgkin; Neoplasms",
        "intervention": "CC-90011; Rifampicin; Itraconazole",
        "url": "https://clinicaltrials.gov/study/NCT02875223",
        "publications": {
          "nct_id": "NCT02875223",
          "study_title": "A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas",
          "publications_found": 2,
          "publications": [
            {
              "pmid": "33046517",
              "citation": "Hollebecque A, Salvagni S, Plummer R, Isambert N, Niccoli P, Capdevila J, Curigliano G, Moreno V, Martin-Romano P, Baudin E, Arias M, Mora S, de Alvaro J, Di Martino J, Parra-Palau JL, Sanchez-Perez T, Aronchik I, Filvaroff EH, Lamba M, Nikolova Z, de Bono JS. Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. Clin Cancer Res. 2021 Jan 15;27(2):438-446. doi: 10.1158/1078-0432.CCR-20-2380. Epub 2020 Oct 12.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33046517/"
            },
            {
              "pmid": "35737639",
              "citation": "Hollebecque A, Salvagni S, Plummer R, Niccoli P, Capdevila J, Curigliano G, Moreno V, de Braud F, de Villambrosia SG, Martin-Romano P, Baudin E, Arias M, de Alvaro J, Parra-Palau JL, Sanchez-Perez T, Aronchik I, Filvaroff EH, Lamba M, Nikolova Z, de Bono JS. Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies. Cancer. 2022 Sep 1;128(17):3185-3195. doi: 10.1002/cncr.34366. Epub 2022 Jun 23.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35737639/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03034200",
        "title": "Phase 2 Study of ONC201 in Neuroendocrine Tumors",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes neuroendocrine tumors, and the patient has a G3 small intestinal NET with liver metastases. The inclusion criteria do not explicitly exclude the patient based on the provided information; there's no mention of age being under 14, and the patient likely has adequate organ function given prior surgery and no stated contraindications. ONC201 represents a potentially useful treatment option given the patient's question regarding further therapy after surgery, and the study has published results in peer-reviewed journals, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Recurrent Neuroendocrine Tumor; Metastatic Neuroendocrine Tumor",
        "intervention": "ONC201",
        "url": "https://clinicaltrials.gov/study/NCT03034200",
        "publications": {
          "nct_id": "NCT03034200",
          "study_title": "Phase 2 Study of ONC201 in Neuroendocrine Tumors",
          "publications_found": 8,
          "publications": [
            {
              "pmid": "23390247",
              "citation": "Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, Zhou JY, Wu GS, El-Deiry WS. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013 Feb 6;5(171):171ra17. doi: 10.1126/scitranslmed.3004828.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/23390247/"
            },
            {
              "pmid": "25927855",
              "citation": "Allen JE, Krigsfeld G, Patel L, Mayes PA, Dicker DT, Wu GS, El-Deiry WS. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Mol Cancer. 2015 May 1;14:99. doi: 10.1186/s12943-015-0346-9.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25927855/"
            },
            {
              "pmid": "25681273",
              "citation": "Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. Cancer Res. 2015 Apr 15;75(8):1668-74. doi: 10.1158/0008-5472.CAN-14-2356. Epub 2015 Feb 13.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25681273/"
            },
            {
              "pmid": "27602582",
              "citation": "Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 2016 Nov 8;7(45):74380-74392. doi: 10.18632/oncotarget.11814.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27602582/"
            },
            {
              "pmid": "29626752",
              "citation": "Hayes-Jordan AA, Ma X, Menegaz BA, Lamhamedi-Cherradi SE, Kingsley CV, Benson JA, Camacho PE, Ludwig JA, Lockworth CR, Garcia GE, Craig SL. Efficacy of ONC201 in Desmoplastic Small Round Cell Tumor. Neoplasia. 2018 May;20(5):524-532. doi: 10.1016/j.neo.2018.02.006. Epub 2018 Apr 5.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/29626752/"
            },
            {
              "pmid": "28767654",
              "citation": "Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLB, Van den Heuvel APJ, Lev A, Garnett MJ, McDermott U, Benes CH, Batchelor TT, Chi AS, Elemento O, Allen JE, El-Deiry WS. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. PLoS One. 2017 Aug 2;12(8):e0180541. doi: 10.1371/journal.pone.0180541. eCollection 2017.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28767654/"
            },
            {
              "pmid": "30907145",
              "citation": "Anderson PM, Hanna R. Defining Moments: Making Time for Virtual Visits and Catalyzing Better Cancer Care. Health Commun. 2020 May;35(6):787-791. doi: 10.1080/10410236.2019.1587695. Epub 2019 Mar 24.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30907145/"
            },
            {
              "pmid": "35022321",
              "citation": "Anderson PM, Trucco MM, Tarapore RS, Zahler S, Thomas S, Gortz J, Mian O, Stoignew M, Prabhu V, Morrow S, Allen JE. Phase II Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma and Desmoplastic Small Round Cell Tumor. Clin Cancer Res. 2022 May 2;28(9):1773-1782. doi: 10.1158/1078-0432.CCR-21-4030.",
              "type": "RESULT",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35022321/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02721732",
        "title": "Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The study explicitly includes 'other rare tumors' which could encompass a well-differentiated neuroendocrine tumor (NET) of the small intestine. The patient's history of surgery and presence of metastatic disease aligns with the study's focus on unresectable/metastatic tumors. While the patient's prior therapies and biomarkers are unknown, the inclusion criteria regarding performance status and lab values appear potentially meetable. The study has published results in peer-reviewed journals, indicating good scientific quality and potential benefit from pembrolizumab.",
        "has_posted_results": true,
        "condition": "Advanced Malignant Solid Neoplasm; Carcinoma of Unknown Primary; Metastatic Adrenal Gland Pheochromocytoma; Metastatic Kidney Medullary Carcinoma; Metastatic Malignant Germ Cell Tumor; Metastatic Malignant Solid Neoplasm; Metastatic Paraganglioma; Metastatic Penile Carcinoma; Metastatic Skin Squamous Cell Carcinoma; Small Cell Carcinoma; Stage III Adrenal Cortex Carcinoma AJCC v7; Stage IV Adrenal Cortex Carcinoma AJCC v7; Stage IV Penile Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Unresectable Adrenal Gland Pheochromocytoma; Unresectable Paraganglioma; Unresectable Skin Squamous Cell Carcinoma; Unresectable Solid Neoplasm; Vascular Neoplasm",
        "intervention": "Laboratory Biomarker Analysis; Pembrolizumab; Questionnaire Administration",
        "url": "https://clinicaltrials.gov/study/NCT02721732",
        "publications": {
          "nct_id": "NCT02721732",
          "study_title": "Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic",
          "publications_found": 12,
          "publications": [
            {
              "pmid": "35999229",
              "citation": "Mendoza TR, Hong DS, Peterson CB, Stephen B, Dumbrava E, Pant S, Tsimberidou AM, Yap TA, Sheshadri A, Altan M, George G, Castillo L, Rodriguez E, Gong J, Subbiah V, Janku F, Fu S, Piha-Paul SA, Ahnert JR, Karp DD, Cleeland C, Meric-Bernstam F, Naing A. Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. Sci Rep. 2022 Aug 23;12(1):14367. doi: 10.1038/s41598-022-16588-3.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35999229/"
            },
            {
              "pmid": "35618285",
              "citation": "Raghav KP, Stephen B, Karp DD, Piha-Paul SA, Hong DS, Jain D, Chudy Onwugaje DO, Abonofal A, Willett AF, Overman M, Smaglo B, Huey RW, Meric-Bernstam F, Varadhachary GR, Naing A. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. J Immunother Cancer. 2022 May;10(5):e004822. doi: 10.1136/jitc-2022-004822.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35618285/"
            },
            {
              "pmid": "34725215",
              "citation": "Pant S, Moyers JT, Naing A. Letter to the editor from Pant et al. J Immunother Cancer. 2021 Nov;9(11):e003991. doi: 10.1136/jitc-2021-003991. No abstract available.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34725215/"
            },
            {
              "pmid": "34241781",
              "citation": "Ferrarotto R, Sousa LG, Qing Y, Kaya D, Stephen B, Jain D, Bell D, Pant S, Tsimberidou AM, Janku F, Blumenschein G, Glisson BS, Ahnert JR, Piha-Paul SA, Lee JJ, Wong MK, Lu C, Meric-Bernstam F, Naing A. Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial. Adv Ther. 2021 Aug;38(8):4581-4591. doi: 10.1007/s12325-021-01807-6. Epub 2021 Jul 9.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34241781/"
            },
            {
              "pmid": "33770291",
              "citation": "Hahn AW, Chahoud J, Campbell MT, Karp DD, Wang J, Stephen B, Tu SM, Pettaway CA, Naing A. Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial. Invest New Drugs. 2021 Oct;39(5):1405-1410. doi: 10.1007/s10637-021-01100-x. Epub 2021 Mar 26.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33770291/"
            },
            {
              "pmid": "33491277",
              "citation": "Tsimberidou AM, Vo HH, Subbiah V, Janku F, Piha-Paul S, Yilmaz B, Gong J, Naqvi MF, Tu SM, Campbell M, Meric-Bernstam F, Naing A. Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. Oncologist. 2021 Jul;26(7):558-e1098. doi: 10.1002/onco.13682. Epub 2021 Feb 12.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33491277/"
            },
            {
              "pmid": "33427689",
              "citation": "Majd N, Waguespack SG, Janku F, Fu S, Penas-Prado M, Xu M, Alshawa A, Kamiya-Matsuoka C, Raza SM, McCutcheon IE, Naing A. Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study. J Immunother Cancer. 2020 Dec;8(2):e001532. doi: 10.1136/jitc-2020-001532.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33427689/"
            },
            {
              "pmid": "33415580",
              "citation": "How JA, Jazaeri A, Westin SN, Sood AK, Ramondetta LM, Xu M, Abonofal A, Karp DD, Subbiah V, Stephen B, Rodon JA, Yang F, Naing A. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Invest New Drugs. 2021 Jun;39(3):829-835. doi: 10.1007/s10637-020-01043-9. Epub 2021 Jan 7.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33415580/"
            },
            {
              "pmid": "32534809",
              "citation": "Frumovitz M, Westin SN, Salvo G, Zarifa A, Xu M, Yap TA, Rodon AJ, Karp DD, Abonofal A, Jazaeri AA, Naing A. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecol Oncol. 2020 Sep;158(3):570-575. doi: 10.1016/j.ygyno.2020.05.682. Epub 2020 Jun 11.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32534809/"
            },
            {
              "pmid": "32303619",
              "citation": "Tapia C, Aung PP, Roy-Chowdhuri S, Xu M, Ouyang F, Alshawa A, Hajjar J, Singh G, Yang V, Castillo L, Le H, Murthy R, Stephen B, Hess KR, Wistuba I, Naing A. Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors. J Immunother Cancer. 2020 Apr;8(1):e000665. doi: 10.1136/jitc-2020-000665.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32303619/"
            },
            {
              "pmid": "32188704",
              "citation": "Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 Mar;8(1):e000347. doi: 10.1136/jitc-2019-000347.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32188704/"
            },
            {
              "pmid": "31533818",
              "citation": "Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, Fu S, Karp DD, Meric-Bernstam F, Naing A. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019 Sep 18;7(1):253. doi: 10.1186/s40425-019-0722-x.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/31533818/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03972488",
        "title": "Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE3",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The patient has a G3 NET of the small intestine with liver metastases, which falls under the GEP-NET category included in the study. The patient's Ki67 of 48% is within the inclusion range of ≥10 and ≤ 55%. While the patient's age, ECOG status, and prior therapies are not specified, the study doesn't explicitly exclude patients based on prior surgery (the patient had a hemicolektomy) and the clinical question is regarding further therapy, suggesting Lutathera could be a viable option. The study is a Phase 3 trial with published results, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Gastro-enteropancreatic Neuroendocrine Tumor",
        "intervention": "Lutathera; 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot); 2.5% Lys-Arg sterile amino acid solution; High dose 60 mg octreotide long-acting repeatable",
        "url": "https://clinicaltrials.gov/study/NCT03972488",
        "publications": {
          "nct_id": "NCT03972488",
          "study_title": "Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET",
          "publications_found": 2,
          "publications": [
            {
              "pmid": "38851203",
              "citation": "Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, Garcia-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5.",
              "type": "RESULT",
              "url": "https://pubmed.ncbi.nlm.nih.gov/38851203/"
            },
            {
              "pmid": "33973550",
              "citation": "Jungels C, Deleporte A. State of the art and future directions in the systemic treatment of neuroendocrine neoplasms. Curr Opin Oncol. 2021 Jul 1;33(4):378-385. doi: 10.1097/CCO.0000000000000740.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33973550/"
            }
          ],
          "status": "from_study_data"
        }
      }
    ],
    "report_file": "C:\\Users\\pia\\OneDrive - Universitaet Bern\\Projects\\NetTubo\\netTubo\\clinical_trials_matches\\patient_2_clinical_trials_llm.txt"
  },
  {
    "patient_id": "3",
    "patient_data": {
      "ID": 3,
      "beschreibung": "G2-Case, geringe SSTR Expression",
      "tumorboard_datum ": 8.2015,
      "main_diagnosis_text": "NET des Dünndarms mit Lymphknoten und Lebermetastasen (ED 2015)\nKoloskopie bei unklaren abdominellen Beschwerden 06/2015: Tumor im Ileum 25 cm oberhalb der Ileozökalklappe. G2 NET.\n07/2015 CT staging Thorax/Abdomen: Primärtumor des Ileums 40 x 40 x 70 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.\n\n07/2015 DOTATOC PET: geringe Speicherung der Leberläsionen.\n07/2015 Hemicolektomie rechts und Ileumteilresektion mit Lymphadenektomie.",
      "Fragestellung": "Weitere Therapie, Everolimus oder PRRT?",
      "Empfehlung": "FDG-PET und Everolimus Therapie starten."
    },
    "matches_found": 10,
    "matches_with_publications": 10,
    "matches_with_posted_results": 10,
    "llm_evaluation_method": "google/gemma-3-27b-it:free",
    "min_relevance_score": 1.0,
    "matches": [
      {
        "nct_id": "NCT03375320",
        "title": "Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE3",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with neuroendocrine tumors (NET), specifically both pancreatic and non-pancreatic (carcinoid) origin, and the patient has a well-differentiated NET of the small intestine with liver metastases. While the patient's ECOG and age are unknown, the inclusion criteria do not immediately exclude them based on the available information. The study investigates cabozantinib, which could be a viable alternative to everolimus or PRRT, addressing the clinical question. Finally, the study has published results in a peer-reviewed journal, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Carcinoid Tumor; Functioning Pancreatic Neuroendocrine Tumor; Intermediate Grade Lung Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Tumor G1; Locally Advanced Lung Neuroendocrine Neoplasm; Locally Advanced Pancreatic Neuroendocrine Tumor; Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm; Low Grade Lung Neuroendocrine Neoplasm; Lung Neuroendocrine Tumor; Lung Neuroendocrine Tumor G2; Metastatic Digestive System Neuroendocrine Neoplasm; Metastatic Digestive System Neuroendocrine Tumor G1; Metastatic Lung Neuroendocrine Neoplasm; Metastatic Lung Neuroendocrine Tumor; Metastatic Pancreatic Neuroendocrine Neoplasm; Metastatic Pancreatic Neuroendocrine Tumor; Metastatic Thymus Neuroendocrine Neoplasm; Neuroendocrine Neoplasm; Neuroendocrine Tumor G2; Non-Functioning Pancreatic Neuroendocrine Tumor; Pancreatic Serotonin-Producing Neuroendocrine Tumor; Thymus Neuroendocrine Tumor; Unresectable Digestive System Neuroendocrine Neoplasm; Unresectable Digestive System Neuroendocrine Tumor G1; Unresectable Lung Neuroendocrine Neoplasm; Unresectable Pancreatic Neuroendocrine Neoplasm; Unresectable Thymus Neuroendocrine Neoplasm",
        "intervention": "Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging; Placebo Administration; Quality-of-Life Assessment; X-Ray Imaging",
        "url": "https://clinicaltrials.gov/study/NCT03375320",
        "publications": {
          "nct_id": "NCT03375320",
          "study_title": "Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "33152282",
              "citation": "Kunz PL. Angiogenesis inhibitors in neuroendocrine tumours: finally coming of age. Lancet Oncol. 2020 Nov;21(11):1395-1397. doi: 10.1016/S1470-2045(20)30560-X. No abstract available.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33152282/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT01578239",
        "title": "A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours",
        "status": "COMPLETED",
        "phase": "PHASE3",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The study focuses on midgut carcinoid tumors, which aligns with the patient's diagnosis of a small intestinal NET. The patient's history of surgery and current consideration of Everolimus or PRRT suggests they are seeking further treatment for progressive disease, fitting the study's inclusion criteria of progressive disease on Octreotide LAR. While the patient's ECOG and biomarker data are missing, the study's criteria regarding KPS (>=60) and Ki67 (<=20%) would need to be met for eligibility. The study is a Phase 3 trial with published results, indicating good scientific quality and a potentially useful alternative treatment option (PRRT with 177Lu-DOTA0-Tyr3-Octreotate) to Everolimus.",
        "has_posted_results": true,
        "condition": "Carcinoid Tumor of the Small Bowel; Neuroendocrine Tumour",
        "intervention": "Octreotide LAR; 177Lu-DOTA0-Tyr3-Octreotate",
        "url": "https://clinicaltrials.gov/study/NCT01578239",
        "publications": {
          "nct_id": "NCT01578239",
          "study_title": "A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours",
          "publications_found": 4,
          "publications": [
            {
              "pmid": "34793718",
              "citation": "Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34793718/"
            },
            {
              "pmid": "32123969",
              "citation": "Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, Baum RP, Caplin M, Ruszniewski P, Delpassand E, Hobday T, Verslype C, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Paganelli G, Severi S, Morse M, Metz DC, Ansquer C, Courbon F, Al-Nahhas A, Baudin E, Giammarile F, Taieb D, Mittra E, Wolin E, O'Dorisio TM, Lebtahi R, Deroose CM, Grana CM, Bodei L, Oberg K, Polack BD, He B, Mariani MF, Gericke G, Santoro P, Erion JL, Ravasi L, Krenning E; NETTER-1 study group. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2372-2382. doi: 10.1007/s00259-020-04709-x. Epub 2020 Mar 2.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32123969/"
            },
            {
              "pmid": "29878866",
              "citation": "Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E; NETTER-1 Study Group. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol. 2018 Sep 1;36(25):2578-2584. doi: 10.1200/JCO.2018.78.5865. Epub 2018 Jun 7.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/29878866/"
            },
            {
              "pmid": "28076709",
              "citation": "Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Oberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28076709/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03070301",
        "title": "A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study focuses on advanced neuroendocrine tumors, which aligns with the patient's diagnosis of a duodenal NET with metastases. The inclusion criteria of Ki67 ≤ 30% and foregut origin (duodenal) are potentially met, although Ki67 is not specified in the patient data. The study investigates Everolimus, which is a treatment option being considered for the patient. While the patient's ECOG and age are unknown, the study requires ECOG 0 or 1, and the patient's prior therapies are not specified, the exclusion criteria regarding prior mTOR inhibitors would need to be confirmed. The study is Phase 2, completed, and has published results, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Neuroendocrine Tumors",
        "intervention": "LEE011; everolimus",
        "url": "https://clinicaltrials.gov/study/NCT03070301",
        "publications": {
          "nct_id": "NCT03070301",
          "study_title": "A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "33640871",
              "citation": "Raj N, Zheng Y, Hauser H, Chou J, Rafailov J, Bou-Ayache J, Sawan P, Chaft J, Chan J, Perez K, Rudin C, Tang L, Reidy-Lagunes D. Ribociclib and everolimus in well-differentiated foregut neuroendocrine tumors. Endocr Relat Cancer. 2021 Apr;28(4):237-246. doi: 10.1530/ERC-20-0446.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33640871/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT01970540",
        "title": "Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors",
        "status": "COMPLETED",
        "phase": "PHASE1",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The inclusion criteria explicitly list 'Gastroenteropancreatic neuroendocrine tumors' which directly matches the patient's diagnosis of a neuroendocrine tumor of the small intestine. The patient's age is likely within the 18-75 range, and assuming a reasonable ECOG performance status (≤1), they would likely meet the inclusion criteria. The combination of lurbinectedin and doxorubicin represents a potential alternative treatment option to consider alongside Everolimus or PRRT, and the study has published results, indicating a level of scientific rigor.",
        "has_posted_results": true,
        "condition": "Endometrial Adenocarcinomas; Neuroendocrine Tumors; Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy",
        "intervention": "lurbinectedin (PM01183); Doxorubicin",
        "url": "https://clinicaltrials.gov/study/NCT01970540",
        "publications": {
          "nct_id": "NCT01970540",
          "study_title": "Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "33704620",
              "citation": "Olmedo ME, Forster M, Moreno V, Lopez-Criado MP, Brana I, Flynn M, Doger B, de Miguel M, Lopez-Vilarino JA, Nunez R, Kahatt C, Cullell-Young M, Zeaiter A, Calvo E. Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study. Invest New Drugs. 2021 Oct;39(5):1275-1283. doi: 10.1007/s10637-020-01025-x. Epub 2021 Mar 11.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33704620/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02875223",
        "title": "A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas",
        "status": "TERMINATED",
        "phase": "PHASE1",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study specifically enriches for grade 2 NETs, which matches the patient's diagnosis of a G2 NET of the small intestine. The inclusion criteria of advanced/unresectable tumors aligns with the patient’s metastatic disease. While the patient’s ECOG status and age are unknown, the study requires ECOG 0-1, which is a reasonable assumption. The intervention, CC-90011, represents a novel therapy option to consider alongside Everolimus or PRRT. Finally, the study has published results in peer-reviewed journals, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Lymphoma, Non-Hodgkin; Neoplasms",
        "intervention": "CC-90011; Rifampicin; Itraconazole",
        "url": "https://clinicaltrials.gov/study/NCT02875223",
        "publications": {
          "nct_id": "NCT02875223",
          "study_title": "A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas",
          "publications_found": 2,
          "publications": [
            {
              "pmid": "33046517",
              "citation": "Hollebecque A, Salvagni S, Plummer R, Isambert N, Niccoli P, Capdevila J, Curigliano G, Moreno V, Martin-Romano P, Baudin E, Arias M, Mora S, de Alvaro J, Di Martino J, Parra-Palau JL, Sanchez-Perez T, Aronchik I, Filvaroff EH, Lamba M, Nikolova Z, de Bono JS. Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. Clin Cancer Res. 2021 Jan 15;27(2):438-446. doi: 10.1158/1078-0432.CCR-20-2380. Epub 2020 Oct 12.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33046517/"
            },
            {
              "pmid": "35737639",
              "citation": "Hollebecque A, Salvagni S, Plummer R, Niccoli P, Capdevila J, Curigliano G, Moreno V, de Braud F, de Villambrosia SG, Martin-Romano P, Baudin E, Arias M, de Alvaro J, Parra-Palau JL, Sanchez-Perez T, Aronchik I, Filvaroff EH, Lamba M, Nikolova Z, de Bono JS. Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies. Cancer. 2022 Sep 1;128(17):3185-3195. doi: 10.1002/cncr.34366. Epub 2022 Jun 23.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35737639/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT01218555",
        "title": "Study of Everolimus (RAD001) in Combination With Lenalidomide",
        "status": "COMPLETED",
        "phase": "PHASE1",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The study investigates everolimus, one of the treatment options the physician is considering. While the study population is broad (advanced refractory solid malignancies), the inclusion criteria do not explicitly exclude NET patients and the patient's advanced disease with liver metastases fits the study's target population. Assuming the patient meets the unspecified ECOG, age, and lab value criteria, they would likely be eligible. The study has published results, indicating a level of scientific rigor and potential benefit, making it a potentially useful source of information for treatment decisions.",
        "has_posted_results": true,
        "condition": "Solid Organ Malignancies; Adenoidcystic Carcinoma; Neuroendocrine Tumors",
        "intervention": "Lenalidomide; Everolimus",
        "url": "https://clinicaltrials.gov/study/NCT01218555",
        "publications": {
          "nct_id": "NCT01218555",
          "study_title": "Study of Everolimus (RAD001) in Combination With Lenalidomide",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "32704173",
              "citation": "Harvey RD, Carthon BC, Lewis C, Hossain MS, Zhang C, Chen Z, Harris WB, Alese OB, Shaib W, Bilen MA, Lawson DH, Wu C, Steuer CE, El-Rayes BF, Khuri FR, Lonial S, Waller EK, Ramalingam SS, Owonikoko TK. Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. Br J Cancer. 2020 Oct;123(8):1228-1234. doi: 10.1038/s41416-020-0988-2. Epub 2020 Jul 24.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32704173/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT01782443",
        "title": "Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes neuroendocrine tumors, and the patient has a G2 NET of the small intestine with liver metastases. The inclusion criteria do not explicitly exclude the patient based on the provided information; no age, ECOG, or specific biomarker contraindications are mentioned. The intervention, Ziv-aflibercept, represents a potentially useful alternative or addition to current treatment options like Everolimus or PRRT being considered for the patient. Finally, the study is completed, has published results, and is a peer-reviewed publication, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Carcinoid Tumor",
        "intervention": "Ziv-aflibercept",
        "url": "https://clinicaltrials.gov/study/NCT01782443",
        "publications": {
          "nct_id": "NCT01782443",
          "study_title": "Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "36395401",
              "citation": "Perez K, Kulke MH, Horick NK, Regan E, Graham C, Scheutz S, Stonely D, Enzinger PC, Fuchs CS, Allen JN, Enzinger AC, Clark JW, Chan JA. A Phase II Study of Ziv-Aflibercept in Patients With Advanced Extrapancreatic Neuroendocrine Tumors. Pancreas. 2022 Aug 1;51(7):763-768. doi: 10.1097/MPA.0000000000002099.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/36395401/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03034200",
        "title": "Phase 2 Study of ONC201 in Neuroendocrine Tumors",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes neuroendocrine tumors, and the patient has a well-defined small intestinal NET with liver metastases. The inclusion criteria do not immediately rule the patient out – there’s no age limit specified that would exclude them, prior therapy number is unlimited, and basic organ function requirements are standard. While the patient's ECOG is unknown, the study requires a Karnofsky score ≥60%, which is a reasonable assumption. ONC201 represents a potentially useful alternative treatment option to Everolimus or PRRT, and the study has published results in peer-reviewed journals, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Recurrent Neuroendocrine Tumor; Metastatic Neuroendocrine Tumor",
        "intervention": "ONC201",
        "url": "https://clinicaltrials.gov/study/NCT03034200",
        "publications": {
          "nct_id": "NCT03034200",
          "study_title": "Phase 2 Study of ONC201 in Neuroendocrine Tumors",
          "publications_found": 8,
          "publications": [
            {
              "pmid": "23390247",
              "citation": "Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, Zhou JY, Wu GS, El-Deiry WS. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013 Feb 6;5(171):171ra17. doi: 10.1126/scitranslmed.3004828.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/23390247/"
            },
            {
              "pmid": "25927855",
              "citation": "Allen JE, Krigsfeld G, Patel L, Mayes PA, Dicker DT, Wu GS, El-Deiry WS. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Mol Cancer. 2015 May 1;14:99. doi: 10.1186/s12943-015-0346-9.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25927855/"
            },
            {
              "pmid": "25681273",
              "citation": "Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. Cancer Res. 2015 Apr 15;75(8):1668-74. doi: 10.1158/0008-5472.CAN-14-2356. Epub 2015 Feb 13.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25681273/"
            },
            {
              "pmid": "27602582",
              "citation": "Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 2016 Nov 8;7(45):74380-74392. doi: 10.18632/oncotarget.11814.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27602582/"
            },
            {
              "pmid": "29626752",
              "citation": "Hayes-Jordan AA, Ma X, Menegaz BA, Lamhamedi-Cherradi SE, Kingsley CV, Benson JA, Camacho PE, Ludwig JA, Lockworth CR, Garcia GE, Craig SL. Efficacy of ONC201 in Desmoplastic Small Round Cell Tumor. Neoplasia. 2018 May;20(5):524-532. doi: 10.1016/j.neo.2018.02.006. Epub 2018 Apr 5.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/29626752/"
            },
            {
              "pmid": "28767654",
              "citation": "Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLB, Van den Heuvel APJ, Lev A, Garnett MJ, McDermott U, Benes CH, Batchelor TT, Chi AS, Elemento O, Allen JE, El-Deiry WS. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. PLoS One. 2017 Aug 2;12(8):e0180541. doi: 10.1371/journal.pone.0180541. eCollection 2017.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28767654/"
            },
            {
              "pmid": "30907145",
              "citation": "Anderson PM, Hanna R. Defining Moments: Making Time for Virtual Visits and Catalyzing Better Cancer Care. Health Commun. 2020 May;35(6):787-791. doi: 10.1080/10410236.2019.1587695. Epub 2019 Mar 24.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30907145/"
            },
            {
              "pmid": "35022321",
              "citation": "Anderson PM, Trucco MM, Tarapore RS, Zahler S, Thomas S, Gortz J, Mian O, Stoignew M, Prabhu V, Morrow S, Allen JE. Phase II Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma and Desmoplastic Small Round Cell Tumor. Clin Cancer Res. 2022 May 2;28(9):1773-1782. doi: 10.1158/1078-0432.CCR-21-4030.",
              "type": "RESULT",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35022321/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03972488",
        "title": "Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE3",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study focuses on GEP-NETs, which includes the patient's small bowel NET. The inclusion criteria specify Grade 2 and 3 tumors, which aligns with the patient's G2 diagnosis. While the patient's ECOG/KPS and biomarker data (Ki67) are missing, the study's criteria don't immediately exclude them, and the patient's history suggests they might meet the requirements. The intervention, Lutathera, is a PRRT therapy, directly addressing the clinical question of whether to pursue PRRT. The study is a Phase 3 trial with published results, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Gastro-enteropancreatic Neuroendocrine Tumor",
        "intervention": "Lutathera; 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot); 2.5% Lys-Arg sterile amino acid solution; High dose 60 mg octreotide long-acting repeatable",
        "url": "https://clinicaltrials.gov/study/NCT03972488",
        "publications": {
          "nct_id": "NCT03972488",
          "study_title": "Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET",
          "publications_found": 2,
          "publications": [
            {
              "pmid": "38851203",
              "citation": "Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, Garcia-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5.",
              "type": "RESULT",
              "url": "https://pubmed.ncbi.nlm.nih.gov/38851203/"
            },
            {
              "pmid": "33973550",
              "citation": "Jungels C, Deleporte A. State of the art and future directions in the systemic treatment of neuroendocrine neoplasms. Curr Opin Oncol. 2021 Jul 1;33(4):378-385. doi: 10.1097/CCO.0000000000000740.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33973550/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT01524783",
        "title": "Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)",
        "status": "COMPLETED",
        "phase": "PHASE3",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The patient has a well-differentiated (G2) neuroendocrine tumor of the small intestine (GI origin), which aligns with the study's inclusion criteria. While the patient's prior therapies are not fully specified, the study allows patients previously treated with SSA, IFN, chemotherapy, or PRRT, provided they have progressed on prior treatment. The clinical question directly addresses one of the study arms (Everolimus), making the intervention potentially useful. Finally, the study is a Phase 3 trial with completed results and 5 publications, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Advanced NET of GI Origin; Advanced NET of Lung Origin; Neuroendocrine Tumors",
        "intervention": "Everolimus; Placebo; Best suportive care (BSC)",
        "url": "https://clinicaltrials.gov/study/NCT01524783",
        "publications": {
          "nct_id": "NCT01524783",
          "study_title": "Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)",
          "publications_found": 5,
          "publications": [
            {
              "pmid": "33560090",
              "citation": "Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, Kulke MH, Pavel M, Singh S. Markers of Systemic Inflammation in Neuroendocrine Tumors: A Pooled Analysis of the RADIANT-3 and RADIANT-4 Studies. Pancreas. 2021 Feb 1;50(2):130-137. doi: 10.1097/MPA.0000000000001745.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33560090/"
            },
            {
              "pmid": "29081664",
              "citation": "Buzzoni R, Carnaghi C, Strosberg J, Fazio N, Singh S, Herbst F, Ridolfi A, Pavel ME, Wolin EM, Valle JW, Oh DY, Yao JC, Pommier R. Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. Onco Targets Ther. 2017 Oct 16;10:5013-5030. doi: 10.2147/OTT.S142087. eCollection 2017.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/29081664/"
            },
            {
              "pmid": "29055056",
              "citation": "Fazio N, Buzzoni R, Delle Fave G, Tesselaar ME, Wolin E, Van Cutsem E, Tomassetti P, Strosberg J, Voi M, Bubuteishvili-Pacaud L, Ridolfi A, Herbst F, Tomasek J, Singh S, Pavel M, Kulke MH, Valle JW, Yao JC. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Sci. 2018 Jan;109(1):174-181. doi: 10.1111/cas.13427. Epub 2017 Nov 9.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/29055056/"
            },
            {
              "pmid": "28838862",
              "citation": "Pavel ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, Degtyarev E, Neary MP, Carnaghi C, Tomasek J, Wolin E, Raderer M, Lahner H, Valle JW, Pommier R, Van Cutsem E, Tesselaar MET, Fave GD, Buzzoni R, Hunger M, Eriksson J, Cella D, Ricci JF, Fazio N, Kulke MH, Yao JC. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1411-1422. doi: 10.1016/S1470-2045(17)30471-0. Epub 2017 Aug 30.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28838862/"
            },
            {
              "pmid": "26703889",
              "citation": "Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016 Mar 5;387(10022):968-977. doi: 10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26703889/"
            }
          ],
          "status": "from_study_data"
        }
      }
    ],
    "report_file": "C:\\Users\\pia\\OneDrive - Universitaet Bern\\Projects\\NetTubo\\netTubo\\clinical_trials_matches\\patient_3_clinical_trials_llm.txt"
  },
  {
    "patient_id": "4",
    "patient_data": {
      "ID": 4,
      "beschreibung": "P-NET G2-Case, Compete Trial analog",
      "tumorboard_datum ": 8.2016,
      "main_diagnosis_text": "NET des Pankreas mit Lymphknoten und Lebermetastasen (ED 2015)\nCT bei unklaren abdominellen Beschwerden 06/2015: Tumor im Pankreas. G2 NET.\n07/2015 CT staging Thorax/Abdomen: Primärtumor des Pankreas 20 x 40 x 30 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.\n\n08/2015 Start Somatuline\n06/2016 DOTATOC PET: Progress der Lebermetastasen, starke Speicherung der Leberläsionen.",
      "Fragestellung": "Weitere Therapie, Everolimus oder PRRT?",
      "Empfehlung": "PRRT starten."
    },
    "matches_found": 9,
    "matches_with_publications": 9,
    "matches_with_posted_results": 9,
    "llm_evaluation_method": "google/gemma-3-27b-it:free",
    "min_relevance_score": 1.0,
    "matches": [
      {
        "nct_id": "NCT03375320",
        "title": "Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE3",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with pancreatic neuroendocrine tumors, matching the patient’s diagnosis. The inclusion criteria allow for patients with progressed disease after prior therapy (somatuline in this case), and continuation of somatostatin analogs is permitted. The patient’s clinical question regarding Everolimus or PRRT makes cabozantinib a potentially useful alternative treatment option. Finally, the study has published results in a peer-reviewed journal, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Carcinoid Tumor; Functioning Pancreatic Neuroendocrine Tumor; Intermediate Grade Lung Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Tumor G1; Locally Advanced Lung Neuroendocrine Neoplasm; Locally Advanced Pancreatic Neuroendocrine Tumor; Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm; Low Grade Lung Neuroendocrine Neoplasm; Lung Neuroendocrine Tumor; Lung Neuroendocrine Tumor G2; Metastatic Digestive System Neuroendocrine Neoplasm; Metastatic Digestive System Neuroendocrine Tumor G1; Metastatic Lung Neuroendocrine Neoplasm; Metastatic Lung Neuroendocrine Tumor; Metastatic Pancreatic Neuroendocrine Neoplasm; Metastatic Pancreatic Neuroendocrine Tumor; Metastatic Thymus Neuroendocrine Neoplasm; Neuroendocrine Neoplasm; Neuroendocrine Tumor G2; Non-Functioning Pancreatic Neuroendocrine Tumor; Pancreatic Serotonin-Producing Neuroendocrine Tumor; Thymus Neuroendocrine Tumor; Unresectable Digestive System Neuroendocrine Neoplasm; Unresectable Digestive System Neuroendocrine Tumor G1; Unresectable Lung Neuroendocrine Neoplasm; Unresectable Pancreatic Neuroendocrine Neoplasm; Unresectable Thymus Neuroendocrine Neoplasm",
        "intervention": "Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging; Placebo Administration; Quality-of-Life Assessment; X-Ray Imaging",
        "url": "https://clinicaltrials.gov/study/NCT03375320",
        "publications": {
          "nct_id": "NCT03375320",
          "study_title": "Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "33152282",
              "citation": "Kunz PL. Angiogenesis inhibitors in neuroendocrine tumours: finally coming of age. Lancet Oncol. 2020 Nov;21(11):1395-1397. doi: 10.1016/S1470-2045(20)30560-X. No abstract available.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33152282/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03736720",
        "title": "Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin",
        "status": "TERMINATED",
        "phase": "PHASE2",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with pancreatic neuroendocrine tumors, matching the patient's diagnosis. While the patient's ECOG and age are unknown, the inclusion criteria specify ECOG 0-2, and there are no age restrictions, so the patient may be eligible. The intervention (liposomal irinotecan, fluorouracil, and leucovorin) represents a potential alternative treatment option to Everolimus or PRRT, which is the clinical question being considered. The study has published results, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Locally Advanced Digestive System Neuroendocrine Carcinoma; Locally Advanced Pancreatic Neuroendocrine Carcinoma; Metastatic Digestive System Neuroendocrine Carcinoma; Metastatic Pancreatic Neuroendocrine Carcinoma; Refractory Digestive System Neuroendocrine Carcinoma; Refractory Pancreatic Neuroendocrine Carcinoma; Unresectable Digestive System Neuroendocrine Carcinoma; Unresectable Pancreatic Neuroendocrine Carcinoma",
        "intervention": "Fluorouracil; Leucovorin; Liposomal Irinotecan; Quality-of-Life Assessment",
        "url": "https://clinicaltrials.gov/study/NCT03736720",
        "publications": {
          "nct_id": "NCT03736720",
          "study_title": "Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "33835977",
              "citation": "Abstracts Presented at the 13th Annual Multidisciplinary Neuroendocrine Tumor Medical Virtual Symposium of the North American Neuroendocrine Tumor Society, October 2-3, 2020. Pancreas. 2021 Mar 1;50(3):441-467. doi: 10.1097/MPA.0000000000001763. No abstract available.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33835977/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03070301",
        "title": "A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes pancreatic NET patients (foregut origin) with characteristics similar to the patient’s G2 NET. While the patient’s ECOG and age are unknown, the study’s criteria of ECOG 0-1 are reasonable, and the patient’s prior Somatuline treatment doesn't appear to be exclusionary. The combination of LEE011 and Everolimus is a potential alternative to PRRT or further Everolimus monotherapy, addressing the clinical question. The study is completed, has published results, and is a Phase 2 trial, indicating a good level of scientific rigor.",
        "has_posted_results": true,
        "condition": "Neuroendocrine Tumors",
        "intervention": "LEE011; everolimus",
        "url": "https://clinicaltrials.gov/study/NCT03070301",
        "publications": {
          "nct_id": "NCT03070301",
          "study_title": "A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "33640871",
              "citation": "Raj N, Zheng Y, Hauser H, Chou J, Rafailov J, Bou-Ayache J, Sawan P, Chaft J, Chan J, Perez K, Rudin C, Tang L, Reidy-Lagunes D. Ribociclib and everolimus in well-differentiated foregut neuroendocrine tumors. Endocr Relat Cancer. 2021 Apr;28(4):237-246. doi: 10.1530/ERC-20-0446.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33640871/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT00510068",
        "title": "Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors",
        "status": "COMPLETED",
        "phase": "PHASE3",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The patient has a pancreatic NET with metastases, which directly matches the study's inclusion criteria of advanced pancreatic NET. While the patient's ECOG and age are not specified, the study accepts ECOG 0-2 and patients ≥ 18 years. The study investigates Everolimus, one of the treatment options the clinician is considering. The study is a Phase 3 trial with published results in peer-reviewed journals, indicating good scientific quality and meaningful data regarding Everolimus' efficacy in this patient population.",
        "has_posted_results": true,
        "condition": "Advanced Neuroendocrine Tumors of Pancreatic Origin",
        "intervention": "Everolimus; Everolimus Placebo",
        "url": "https://clinicaltrials.gov/study/NCT00510068",
        "publications": {
          "nct_id": "NCT00510068",
          "study_title": "Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors",
          "publications_found": 5,
          "publications": [
            {
              "pmid": "33560090",
              "citation": "Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, Kulke MH, Pavel M, Singh S. Markers of Systemic Inflammation in Neuroendocrine Tumors: A Pooled Analysis of the RADIANT-3 and RADIANT-4 Studies. Pancreas. 2021 Feb 1;50(2):130-137. doi: 10.1097/MPA.0000000000001745.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33560090/"
            },
            {
              "pmid": "28113028",
              "citation": "Yao JC, Voi M, Lincy J, Pavel M. Reply to V. Amoroso et al. J Clin Oncol. 2017 May 1;35(13):1488-1489. doi: 10.1200/JCO.2017.71.3875. Epub 2017 Jan 23. No abstract available.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28113028/"
            },
            {
              "pmid": "27621394",
              "citation": "Yao JC, Pavel M, Lombard-Bohas C, Van Cutsem E, Voi M, Brandt U, He W, Chen D, Capdevila J, de Vries EGE, Tomassetti P, Hobday T, Pommier R, Oberg K. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. J Clin Oncol. 2016 Nov 10;34(32):3906-3913. doi: 10.1200/JCO.2016.68.0702. Epub 2016 Sep 30.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27621394/"
            },
            {
              "pmid": "25479584",
              "citation": "Lombard-Bohas C, Yao JC, Hobday T, Van Cutsem E, Wolin EM, Panneerselvam A, Stergiopoulos S, Shah MH, Capdevila J, Pommier R. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial. Pancreas. 2015 Mar;44(2):181-9. doi: 10.1097/MPA.0000000000000262.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25479584/"
            },
            {
              "pmid": "21306238",
              "citation": "Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/21306238/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT01970540",
        "title": "Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors",
        "status": "COMPLETED",
        "phase": "PHASE1",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The inclusion criteria explicitly list 'Gastroenteropancreatic neuroendocrine tumors' which directly matches the patient's diagnosis of a pancreatic NET with liver metastases. While the patient's ECOG and age are not specified, the study allows for ECOG 0-1 (or 0-2 for certain cohorts) and an age range of 18-75, meaning the patient *could* be eligible. The combination of lurbinectedin and doxorubicin represents a potential alternative treatment option to consider alongside Everolimus or PRRT, especially given the progression on Somatuline. The study is a completed Phase 1 trial with published results, indicating a level of scientific rigor.",
        "has_posted_results": true,
        "condition": "Endometrial Adenocarcinomas; Neuroendocrine Tumors; Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy",
        "intervention": "lurbinectedin (PM01183); Doxorubicin",
        "url": "https://clinicaltrials.gov/study/NCT01970540",
        "publications": {
          "nct_id": "NCT01970540",
          "study_title": "Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "33704620",
              "citation": "Olmedo ME, Forster M, Moreno V, Lopez-Criado MP, Brana I, Flynn M, Doger B, de Miguel M, Lopez-Vilarino JA, Nunez R, Kahatt C, Cullell-Young M, Zeaiter A, Calvo E. Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study. Invest New Drugs. 2021 Oct;39(5):1275-1283. doi: 10.1007/s10637-020-01025-x. Epub 2021 Mar 11.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33704620/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02264665",
        "title": "OPALINE : A Study Of Morbidity And Mortality At 2 Years",
        "status": "COMPLETED",
        "phase": "N/A",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with unresectable or metastatic pancreatic neuroendocrine tumors, matching the patient’s diagnosis. The inclusion criteria allow for patients receiving everolimus as a treatment line, directly addressing the clinical question of whether everolimus is a suitable next step. While the patient’s prior therapies and ECOG status are unknown, the study doesn't exclude patients based on prior somatostatin analog treatment and allows for multiple lines of therapy. The study is completed, has published results, and a peer-reviewed publication, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive",
        "intervention": "sunitinib; everolimus; chemotherapies recommended in france",
        "url": "https://clinicaltrials.gov/study/NCT02264665",
        "publications": {
          "nct_id": "NCT02264665",
          "study_title": "OPALINE : A Study Of Morbidity And Mortality At 2 Years",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "35419649",
              "citation": "Smith D, Lepage C, Vicaut E, Dominguez S, Coriat R, Dubreuil O, Lecomte T, Baudin E, Venat Bouvet L, Samalin E, Santos A, Borie O, Bisot-Locard S, Goichot B, Lombard-Bohas C. Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study. Adv Ther. 2022 Jun;39(6):2731-2748. doi: 10.1007/s12325-022-02103-7. Epub 2022 Apr 13.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35419649/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02875223",
        "title": "A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas",
        "status": "TERMINATED",
        "phase": "PHASE1",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes grade 2 NETs, which matches the patient’s diagnosis of a G2 NET of the pancreas. The inclusion criteria of advanced/unresectable tumors aligns with the patient’s metastatic disease. While the patient’s ECOG status and age are unknown, the study requires ECOG 0-1, which is a reasonable assumption. The intervention, CC-90011, represents a novel therapy option to consider alongside Everolimus or PRRT. Finally, the study has published results in peer-reviewed journals, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Lymphoma, Non-Hodgkin; Neoplasms",
        "intervention": "CC-90011; Rifampicin; Itraconazole",
        "url": "https://clinicaltrials.gov/study/NCT02875223",
        "publications": {
          "nct_id": "NCT02875223",
          "study_title": "A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas",
          "publications_found": 2,
          "publications": [
            {
              "pmid": "33046517",
              "citation": "Hollebecque A, Salvagni S, Plummer R, Isambert N, Niccoli P, Capdevila J, Curigliano G, Moreno V, Martin-Romano P, Baudin E, Arias M, Mora S, de Alvaro J, Di Martino J, Parra-Palau JL, Sanchez-Perez T, Aronchik I, Filvaroff EH, Lamba M, Nikolova Z, de Bono JS. Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. Clin Cancer Res. 2021 Jan 15;27(2):438-446. doi: 10.1158/1078-0432.CCR-20-2380. Epub 2020 Oct 12.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33046517/"
            },
            {
              "pmid": "35737639",
              "citation": "Hollebecque A, Salvagni S, Plummer R, Niccoli P, Capdevila J, Curigliano G, Moreno V, de Braud F, de Villambrosia SG, Martin-Romano P, Baudin E, Arias M, de Alvaro J, Parra-Palau JL, Sanchez-Perez T, Aronchik I, Filvaroff EH, Lamba M, Nikolova Z, de Bono JS. Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies. Cancer. 2022 Sep 1;128(17):3185-3195. doi: 10.1002/cncr.34366. Epub 2022 Jun 23.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35737639/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT01218555",
        "title": "Study of Everolimus (RAD001) in Combination With Lenalidomide",
        "status": "COMPLETED",
        "phase": "PHASE1",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The patient has a NET with liver metastases, and the study investigates everolimus, one of the treatment options the clinician is considering. The inclusion criteria allow for patients with advanced refractory solid malignancies, which fits the patient’s situation. While the patient's ECOG and age are unknown, the study accepts ECOG 0-2 and patients ≥ 18 years. The exclusion criteria regarding prior therapies (at least 4 weeks off treatment) and liver function (AST/ALT ≤ 2x ULN, or ≤ 5x ULN with liver mets) don't appear to immediately rule the patient out, assuming they meet these criteria. The study is a Phase 1 trial with published results, indicating a level of scientific rigor.",
        "has_posted_results": true,
        "condition": "Solid Organ Malignancies; Adenoidcystic Carcinoma; Neuroendocrine Tumors",
        "intervention": "Lenalidomide; Everolimus",
        "url": "https://clinicaltrials.gov/study/NCT01218555",
        "publications": {
          "nct_id": "NCT01218555",
          "study_title": "Study of Everolimus (RAD001) in Combination With Lenalidomide",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "32704173",
              "citation": "Harvey RD, Carthon BC, Lewis C, Hossain MS, Zhang C, Chen Z, Harris WB, Alese OB, Shaib W, Bilen MA, Lawson DH, Wu C, Steuer CE, El-Rayes BF, Khuri FR, Lonial S, Waller EK, Ramalingam SS, Owonikoko TK. Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. Br J Cancer. 2020 Oct;123(8):1228-1234. doi: 10.1038/s41416-020-0988-2. Epub 2020 Jul 24.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32704173/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT01824875",
        "title": "Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The study explicitly focuses on pancreatic neuroendocrine tumors, matching the patient's diagnosis. While the patient's ECOG and age are unknown, the inclusion criteria require ECOG 0-1 and do not specify an age limit, and the patient's prior Somatuline treatment is permissible given the criteria. The intervention, temozolomide with or without capecitabine, represents a potential alternative treatment option to Everolimus or PRRT, addressing the clinical question. Finally, the study has published results in a peer-reviewed journal, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma",
        "intervention": "temozolomide; capecitabine",
        "url": "https://clinicaltrials.gov/study/NCT01824875",
        "publications": {
          "nct_id": "NCT01824875",
          "study_title": "Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "36260828",
              "citation": "Kunz PL, Graham NT, Catalano PJ, Nimeiri HS, Fisher GA, Longacre TA, Suarez CJ, Martin BA, Yao JC, Kulke MH, Hendifar AE, Shanks JC, Shah MH, Zalupski MM, Schmulbach EL, Reidy-Lagunes DL, Strosberg JR, O'Dwyer PJ, Benson AB 3rd. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). J Clin Oncol. 2023 Mar 1;41(7):1359-1369. doi: 10.1200/JCO.22.01013. Epub 2022 Oct 19.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/36260828/"
            }
          ],
          "status": "from_study_data"
        }
      }
    ],
    "report_file": "C:\\Users\\pia\\OneDrive - Universitaet Bern\\Projects\\NetTubo\\netTubo\\clinical_trials_matches\\patient_4_clinical_trials_llm.txt"
  },
  {
    "patient_id": "5",
    "patient_data": {
      "ID": 5,
      "beschreibung": "P-NET G2-Case Initial",
      "tumorboard_datum ": 6.2015,
      "main_diagnosis_text": "NET des Pankreas mit Lymphknoten und Lebermetastasen (ED 2015)\nCT bei unklaren abdominellen Beschwerden 06/2015: Tumor im Pankreas. G2 NET.\n07/2015 CT staging Thorax/Abdomen: Primärtumor des Pankreas 20 x 40 x 30 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.\n\n06/2015 DOTATOC PET: starke Speicherung der Läsionen.",
      "Fragestellung": "Weitere Therapie, Somatuline oder PRRT?",
      "Empfehlung": "PRRT starten."
    },
    "matches_found": 5,
    "matches_with_publications": 5,
    "matches_with_posted_results": 5,
    "llm_evaluation_method": "google/gemma-3-27b-it:free",
    "min_relevance_score": 1.0,
    "matches": [
      {
        "nct_id": "NCT01970540",
        "title": "Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors",
        "status": "COMPLETED",
        "phase": "PHASE1",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The inclusion criteria explicitly list 'Gastroenteropancreatic neuroendocrine tumors' which directly matches the patient's diagnosis of a pancreatic NET. The patient's age is likely within the 18-75 range, and assuming a reasonable ECOG PS (≤1), they would likely meet the inclusion criteria. The combination of lurbinectedin and doxorubicin could be a potential treatment option to consider alongside somatuline or PRRT, especially given the progression of the disease with liver and lymph node metastases. The study is completed, has published results, and therefore meets the quality criteria.",
        "has_posted_results": true,
        "condition": "Endometrial Adenocarcinomas; Neuroendocrine Tumors; Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy",
        "intervention": "lurbinectedin (PM01183); Doxorubicin",
        "url": "https://clinicaltrials.gov/study/NCT01970540",
        "publications": {
          "nct_id": "NCT01970540",
          "study_title": "Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "33704620",
              "citation": "Olmedo ME, Forster M, Moreno V, Lopez-Criado MP, Brana I, Flynn M, Doger B, de Miguel M, Lopez-Vilarino JA, Nunez R, Kahatt C, Cullell-Young M, Zeaiter A, Calvo E. Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study. Invest New Drugs. 2021 Oct;39(5):1275-1283. doi: 10.1007/s10637-020-01025-x. Epub 2021 Mar 11.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33704620/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02875223",
        "title": "A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas",
        "status": "TERMINATED",
        "phase": "PHASE1",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes grade 2 NETs, which matches the patient’s diagnosis of a G2 NET of the pancreas. The inclusion criteria of advanced/unresectable tumors aligns with the patient’s metastatic disease. While the patient’s ECOG and age are unknown, the study requires ECOG 0-1, which is a reasonable assumption. The intervention, CC-90011, represents a novel therapy that could be considered for relapsed/refractory disease, addressing the clinical question of alternative therapies to somatuline or PRRT. Finally, the study has published results in peer-reviewed journals, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Lymphoma, Non-Hodgkin; Neoplasms",
        "intervention": "CC-90011; Rifampicin; Itraconazole",
        "url": "https://clinicaltrials.gov/study/NCT02875223",
        "publications": {
          "nct_id": "NCT02875223",
          "study_title": "A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas",
          "publications_found": 2,
          "publications": [
            {
              "pmid": "33046517",
              "citation": "Hollebecque A, Salvagni S, Plummer R, Isambert N, Niccoli P, Capdevila J, Curigliano G, Moreno V, Martin-Romano P, Baudin E, Arias M, Mora S, de Alvaro J, Di Martino J, Parra-Palau JL, Sanchez-Perez T, Aronchik I, Filvaroff EH, Lamba M, Nikolova Z, de Bono JS. Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. Clin Cancer Res. 2021 Jan 15;27(2):438-446. doi: 10.1158/1078-0432.CCR-20-2380. Epub 2020 Oct 12.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33046517/"
            },
            {
              "pmid": "35737639",
              "citation": "Hollebecque A, Salvagni S, Plummer R, Niccoli P, Capdevila J, Curigliano G, Moreno V, de Braud F, de Villambrosia SG, Martin-Romano P, Baudin E, Arias M, de Alvaro J, Parra-Palau JL, Sanchez-Perez T, Aronchik I, Filvaroff EH, Lamba M, Nikolova Z, de Bono JS. Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies. Cancer. 2022 Sep 1;128(17):3185-3195. doi: 10.1002/cncr.34366. Epub 2022 Jun 23.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35737639/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT01525550",
        "title": "A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors",
        "status": "COMPLETED",
        "phase": "PHASE4",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study specifically focuses on well-differentiated pancreatic neuroendocrine tumors, which matches the patient’s G2 NET diagnosis. While the patient’s prior therapies and ECOG status are unknown, the exclusion criteria regarding prior tyrosine kinase inhibitors or mTOR inhibitors don't immediately rule the patient out, and the disease progression criteria could apply given the 2015 diagnosis and current need for further therapy. Sunitinib is a potentially useful treatment option to consider alongside somatuline or PRRT. The study is completed, has published results, and a publication exists, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Well-differentiated Pancreatic Neuroendocrine Tumor",
        "intervention": "sunitinib",
        "url": "https://clinicaltrials.gov/study/NCT01525550",
        "publications": {
          "nct_id": "NCT01525550",
          "study_title": "A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "33411058",
              "citation": "Fazio N, Kulke M, Rosbrook B, Fernandez K, Raymond E. Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib. Target Oncol. 2021 Jan;16(1):27-35. doi: 10.1007/s11523-020-00784-0. Epub 2021 Jan 7.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33411058/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03034200",
        "title": "Phase 2 Study of ONC201 in Neuroendocrine Tumors",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with neuroendocrine tumors, and the patient has a pancreatic NET with metastases. The inclusion criteria do not immediately rule the patient out – there’s no age limit specified that would exclude them, prior therapies are allowed, and the requirement for detectable lesions is met. While ECOG/Karnofsky is not specified for the patient, the study requires a performance status ≥60%, which is reasonable to assume the patient might meet. ONC201 represents a potentially useful alternative treatment option to somatuline or PRRT, and the study has published results in peer-reviewed journals, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Recurrent Neuroendocrine Tumor; Metastatic Neuroendocrine Tumor",
        "intervention": "ONC201",
        "url": "https://clinicaltrials.gov/study/NCT03034200",
        "publications": {
          "nct_id": "NCT03034200",
          "study_title": "Phase 2 Study of ONC201 in Neuroendocrine Tumors",
          "publications_found": 8,
          "publications": [
            {
              "pmid": "23390247",
              "citation": "Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, Zhou JY, Wu GS, El-Deiry WS. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013 Feb 6;5(171):171ra17. doi: 10.1126/scitranslmed.3004828.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/23390247/"
            },
            {
              "pmid": "25927855",
              "citation": "Allen JE, Krigsfeld G, Patel L, Mayes PA, Dicker DT, Wu GS, El-Deiry WS. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Mol Cancer. 2015 May 1;14:99. doi: 10.1186/s12943-015-0346-9.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25927855/"
            },
            {
              "pmid": "25681273",
              "citation": "Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. Cancer Res. 2015 Apr 15;75(8):1668-74. doi: 10.1158/0008-5472.CAN-14-2356. Epub 2015 Feb 13.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25681273/"
            },
            {
              "pmid": "27602582",
              "citation": "Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 2016 Nov 8;7(45):74380-74392. doi: 10.18632/oncotarget.11814.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27602582/"
            },
            {
              "pmid": "29626752",
              "citation": "Hayes-Jordan AA, Ma X, Menegaz BA, Lamhamedi-Cherradi SE, Kingsley CV, Benson JA, Camacho PE, Ludwig JA, Lockworth CR, Garcia GE, Craig SL. Efficacy of ONC201 in Desmoplastic Small Round Cell Tumor. Neoplasia. 2018 May;20(5):524-532. doi: 10.1016/j.neo.2018.02.006. Epub 2018 Apr 5.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/29626752/"
            },
            {
              "pmid": "28767654",
              "citation": "Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLB, Van den Heuvel APJ, Lev A, Garnett MJ, McDermott U, Benes CH, Batchelor TT, Chi AS, Elemento O, Allen JE, El-Deiry WS. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. PLoS One. 2017 Aug 2;12(8):e0180541. doi: 10.1371/journal.pone.0180541. eCollection 2017.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28767654/"
            },
            {
              "pmid": "30907145",
              "citation": "Anderson PM, Hanna R. Defining Moments: Making Time for Virtual Visits and Catalyzing Better Cancer Care. Health Commun. 2020 May;35(6):787-791. doi: 10.1080/10410236.2019.1587695. Epub 2019 Mar 24.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30907145/"
            },
            {
              "pmid": "35022321",
              "citation": "Anderson PM, Trucco MM, Tarapore RS, Zahler S, Thomas S, Gortz J, Mian O, Stoignew M, Prabhu V, Morrow S, Allen JE. Phase II Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma and Desmoplastic Small Round Cell Tumor. Clin Cancer Res. 2022 May 2;28(9):1773-1782. doi: 10.1158/1078-0432.CCR-21-4030.",
              "type": "RESULT",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35022321/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03972488",
        "title": "Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE3",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The patient has a G2 pancreatic NET with liver metastases, which falls within the GEP-NET inclusion criteria of the study. While the patient's ECOG and age are unknown, the study requires a KPS ≥ 60 (equivalent to ECOG 0-1) and includes patients ≥ 15 years old, so these are not immediately disqualifying. The patient’s DOTATOC PET scan indicates somatostatin receptor expression, fulfilling a key inclusion criterion. The study investigates Lutathera, a PRRT therapy, which directly addresses the clinical question of whether to pursue Somatuline or PRRT. The study is a Phase 3 trial with published results, indicating good scientific quality.",
        "has_posted_results": true,
        "condition": "Gastro-enteropancreatic Neuroendocrine Tumor",
        "intervention": "Lutathera; 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot); 2.5% Lys-Arg sterile amino acid solution; High dose 60 mg octreotide long-acting repeatable",
        "url": "https://clinicaltrials.gov/study/NCT03972488",
        "publications": {
          "nct_id": "NCT03972488",
          "study_title": "Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET",
          "publications_found": 2,
          "publications": [
            {
              "pmid": "38851203",
              "citation": "Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, Garcia-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5.",
              "type": "RESULT",
              "url": "https://pubmed.ncbi.nlm.nih.gov/38851203/"
            },
            {
              "pmid": "33973550",
              "citation": "Jungels C, Deleporte A. State of the art and future directions in the systemic treatment of neuroendocrine neoplasms. Curr Opin Oncol. 2021 Jul 1;33(4):378-385. doi: 10.1097/CCO.0000000000000740.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33973550/"
            }
          ],
          "status": "from_study_data"
        }
      }
    ],
    "report_file": "C:\\Users\\pia\\OneDrive - Universitaet Bern\\Projects\\NetTubo\\netTubo\\clinical_trials_matches\\patient_5_clinical_trials_llm.txt"
  }
]